



A medical company creating
digital therapeutics products
for cancer patients.

Prosoma Opportunity

Multi - billion dollar medium-term investment opportunity



We develop a portfolio of medical software products that cover **the entirety of behavioural treatment needs** of cancer patients.



Our clinically validated digital therapeutics platform will be **prescribed** by doctors and therapist in Germany, and it will be reimbursed by the local healthcare system in **Q1 2022**.



We aim to become **#1 global digital therapeutics solution** for oncology and we have a pathway to get there.

Problem

Healthcare systems around the world fail to deliver sufficient behavioral and psychological support for cancer patients.



Healthcare systems are not designed to deliver comprehensive care for cancer patients:

- Behavioural support is incredibly labour intensive.
- There is a significant shortage of required skilled personnel (eg. psycho-oncologists) who are available to help.
- There are financial, geographical and psychological barriers.



Cancer patients lack behavioral and psychological support:

- **147%** more likely to require emergency care.
- **75%** more likely to be hospitalised.
- **73%** more likely to be re-hospitalised within 30 days.
- **32%** higher annual total cost of care.



Solution

Prosoma Digital Therapeutics Platform covers all of the patient's behavioural needs and is an essential element of the personalised cancer patient journey.



Products

Medical self-care mobile applications designed to deliver personalised therapeutic methods for each patient, based on diagnostics and outcomes.



DIAGNOSTICS & ANALYTICS
Tools designed to track the therapy's progress and gather user feedback.

THERAPEUTIC MIX ALGORITHM
Based on the therapeutic protocol and adjusted by live data.

CBT
The most acclaimed behavioural methods designed by world-renowned experts.



BEHAVIOUR CHANGE
Digital reinforcement tools creating and reinforcing habits in an engaging and rewarding way.

Products' development roadmap

We have a clinically proven process and a CE Medical Device platform allowing us to introduce all needed modules and apps to the market.



| Module | Stage | Product discovery | Development | Clinical validation | Regulatory | Launch for prescription |
|--------------------|-------------------------------|-------------------|-------------|---------------------|------------|-------------------------|
| Living well | Adaptation to diagnosis | | | | | Q1 22 |
| Vitaly | Cancer related fatigue | | | | | H2 22 |
| Revive | Life coaching after treatment | | | | | H1 23 |
| Spring up | Fear of cancer recurrence | | | | | H1 23 |

Why Now?

Stars are aligning for digital therapeutics in oncology.

01. Digital health boom

Telemedicine and COVID-19 accelerated digital health development.

02. Reimbursement regulations for DTx

Rising numbers of countries implement fast-tracks for digital therapeutics on prescription.

03. Social trust for mental health apps

Widespread clinical validation and real world data.

2017

US FDA regulatory pathway for DTx

2020

German BfArM regulatory pathway for DTx

2021

>20 Apps reimbursed worldwide

2021

9 countries with fast-tracks for DTx

WE
ARE
HERE


Competitive Advantage

Only a platform that provides personalised journey for every cancer patient can become a market leader.

| | Gender specific | Treatment stage specific | Personalised | Symptoms reporting | Complete behavioural needs |
|--|-----------------|--------------------------|--------------|--------------------|----------------------------|
|  | ✓ | ✓ | ✓ | ✓ | ✓ |
|  | ✗ | ✗ | ✓ | ✓ | ✗ |
|  | ✗ | ✗ | ✗ | ✓ | ✓ |
|  | ✗ | ✗ | ✗ | ✓ | ✗ |
|  | ✗ | ✗ | ✓ | ✓ | ✓ |


Market size

Digital therapeutics for oncology is a multi-billion growing opportunity.
1000 EUR average reimbursement price-point based on BfArM accepted products.



Digital therapeutics market

CAGR 20,5%*




* ICT&Health report

<https://ictandhealth.com/news/digital-therapeut-ics-a-comprehensive-review-and-outlook/>

Revenue model

Prescribed digital therapeutics interventions will be financed in the same way as medicine.



Go-to-market roadmap

Prosoma will be validated with RCT and prescribed in Germany by Q1 22.

| CE Mark | HIPAA compliance | Retrospective evidence | DIGA provisional acceptance | Clinical trials results | US Pivotal study | FDA Fast-track submission |
|---------|------------------|------------------------|-----------------------------|-------------------------|------------------|---------------------------|
| | | | Q4 21 | Q2 22 | Q4 22 | Q4 22 |

EQUITY VALUE² (handwritten label with arrow pointing to DIGA provisional acceptance)

EQUITY VALUE³ (handwritten label with arrow pointing to Clinical trials results)


FIRST PRESCRIPTION (handwritten label with arrow pointing to Q4 21)

Step 1 - German market

The biggest hospital chain in Europe is leading Prosoma's introduction to the German market.



Doctors asked for digital therapeutics prescriptions - Q4 2020*



- 19% are currently not willing to prescribe DIGA Apps
- 25% are reserved due to lack of clinical evidence
- 28% are already prescribing DIGA Apps
- 29% are willing to prescribe DIGA Apps

* https://www.bitkom.org/sites/default/files/2020-07/prasentation_digitalhealth2020.pdf

• 550k insured cancer patients per year

• 550M EUR DTx Oncology market

• Oncology market

• 0 current players

Clinical evidence

Prosoma is based on DIGA compliant clinical evidence:

01 Feasibility and randomised controlled trials compliant with DIGA/FDA standards

02 Retrospective clinical studies meta-analysis

03 German and US standards of treatment

Feasibility studies:

Feasibility protocol: *two-arm randomised control study to determine the feasibility of a guided, mobile -based self-help CBT programme to enhance health-related quality of life among women with cancer.*

 Asklepios:
Q3 21



Primary Investigator:
PD Dr Med
Georgia Schilling

 Memorial
Care:
Q4 21



Primary Investigator:
Mariusz Wirga,
M.D.



Clinical evidence

Randomised Controlled Trial protocol:

Evaluation of the effectiveness of the mobile application-based cognitive-behavioural intervention (MA-CBT) in comparison to standard psycho-oncological care in the process of primary oncological treatment of breast cancer patients: a multi-sided prospective two-arm randomised clinical trial.

Primary Investigators:



Q3 21 - Q1 22



**Prof
Tit Albreht**



**Dr hab. Michał
Jarzab**



**Prof Rafał
Matkowski**



**Prof Tomasz
Pawłowski**



UNIwersytet ŚLĄSKI
W KATOWICACH

Management team



Marek Ostrowski

Chief Executive Officer

Psycho-oncologist, creative thinker and successful entrepreneur. 12+ years of experience in start-up management. Already exited from Luxon - EMEA Deloitte Fast 500 company.



Andrzej Jończyk, M.D.

Chief Strategy Officer

Medical doctor and successful tech entrepreneur. 8+ years of experience in European and US markets, build a New York Forbes 30 under 30 company.



Piotr Grudziński

Chief Operating Officer

Ex-Microsoft, Ex-Asklepios Kliniken, 12+ years of experience in operational management in Germany and Poland, graduate from Hochschule Furtwangen University.



Prof. Ewa Wojtyna

Chief Scientific Officer

Medical doctor, psycho-oncologist, certified CBT psychotherapist, University professor with +10 years experience in psychological and medical research.



Wojtek Bieroński

Chief Product Officer

Digital Health Product Manager, psychologist, MedTech specialist, + 5 years experience in Digital Therapeutics .



Grzegorz Sołyga

Chief Financial Officer

Financial controller and analysis leader. Experienced in German and Polish market, CIMA P2 specialist.

Product development and advisory team



Prof Tit Albreht

Coordinator of the Joint Action iPAAC at National Institute of Public Health of Slovenia, WHO consultant, one of the leaders of the European cancer policy.



dr Christa Digeleemann

Psycho-oncologist, researcher, author and one of the leaders in German psycho-oncology policy.



dr Margarete Isermann

Psycho-oncologist, researcher, author of "Curriculum Psycho-oncology" - the programme certified by the German Psycho-oncology Society (DKG).



dr Georgia Schilling

Medical Doctor, Oncologist at Asklepios Kliniken, researcher, specialist in palliative care and rheumatology.



dr Mariusz Wirga

Medical director for the PsychoSocial Oncology programme at the Long Beach Medical Center, certified psychiatrist specialising in Cognitive Behavioural Therapy.



dr Christoph Partsch

Attorney, specialising in intellectual property law, doctorate at Christian Albrechts Universität Kiel.



Leesa Soulodre

leader in deeptech innovation and digital transformation, led companies from seed to \$14B USD into new markets and supported in the raising of over USD40M



Krzysztof Kuwałek

20 years of track record as a successful and professional executive. Experience includes work for start-up and well-established companies in 15+ countries



dr Lahiru Russell

Research Fellow at Deakin University, Melbourne, Oncology researcher, Mindfulness trainer and clinical trials specialist.

Prosoma

Top expertise and experience. Perfectly prepared for the boom.

01 Experienced entrepreneurs

Project managed by experienced entrepreneurs versed in international environments.

02 World's best scientific team

International team of clinicians, university professors and world-leading psycho-oncologists. More than 100 top publications and presentations between them.

03 UX design focused

Applications build by UX and behavioural design specialists.

04 Experienced Tech team

Working with best app developers & data scientists.

05 Strong research background

Top notch researchers with years of experience and many published clinical trials.

06 Patient focused

Products designed with the patient at the heart of the process.

Partners

Clinical partners:



*National Cancer
Institute Poland*



Asklepios Kliniken Germany



*Memorial
Care US*



*Lower Silesian Center
for Oncology*

Commercialisation partners:



MaRS, Germany



EVERSANA™

Eversana US

Business accelerating programs:



*University
of California
San Francisco*



Incredibles



**UNIVERSITY OF
CAMBRIDGE**

Cambridge

Investment Plan

Three VC's on board and a direct pathway to Series A.




BlackPearls.vc



| Closed | | | | Pending | Planned |
|--------------------|----------------|------------|------------|----------------------|-----------|
| Pre-seed VC Equity | Seed VC Equity | NCBR Grant | PARP Grant | VC Convertible notes | Series-A |
| Q4 2018 | Q3 2020 | Q4 2020 | Q1 2021 | Q3 2021 | Q2 2022 |
| 290k EUR | 640k EUR | 1050k EUR | 100k EUR | 950k EUR | 4500k EUR |

Founding objectives in k EUR



- Product development
- Commercialisation US
- Commercialisation EU
- Clinical trials

Would you like to join Prosoma just before we take off?

Marek Ostrowski

marek@prosoma.com

+48 502 130 930

